Clinical trials: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic…
- Trial name
- NCT06126731
- Testing
- Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration Resistant Prostate Cancer
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
- Trial name
- PRINCE (NCT03658447)
- Testing
- Pembrolizumab, 177Lu-PSMA
- Where
- 4 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer, Castration-resistant Prostate Cancer
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
Metastatic castration-resistant Prostate cancer (mCRPC) is a very late stage of prostate cancer with poor prognosis. Although there are several treatment strategies available for mCRPC, these drugs are not always effective for…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Drug
- Trial name
- NCT03356444
- Testing
- Abiraterone Acetate, Docetaxel
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Metastatic Castration-resistant Prostate Cancer
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety of RC48-ADC in patients with mCRPC who have progressed after NHT.
- Trial name
- NCT05955209
- Testing
- Disitamab Vedotin（RC48-ADC）
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Castration Resistant Prostate Cancer
Combination Study of AZD5069 and Enzalutamide.
ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC).
- Trial name
- ACE (NCT03177187)
- Testing
- AZD5069, Enzalutamide 40 MG
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Castration-Resistant Prostatic Cancer
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen…
- Trial name
- NCT04404140
- Testing
- Ipatasertib, Atezolizumab, Docetaxel
- Where
- 9 sites in France, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-resistant Prostate Cancer
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to…
- Trial name
- NCT06100705
- Testing
- Testosterone Cypionate, Sipuleucel-T
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who…
- Trial name
- ARTISAN (NCT07214961)
- Testing
- AB001
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ARTBIO Inc.
Prostatic Neoplasms
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
- Trial name
- NCT04898634
- Testing
- JNJ-78278343
- Where
- 17 sites in United States, China and 4 more
- Volunteers
- 216 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer
imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS
The PROMPT study aims to routinely implement genomic pre-sorting of metastatic castration-resistant prostate cancer (mCRPC) patients for personalized treatment (e.g. immuno-, PARP inhibitors, or platinum-therapy).
- Trial name
- PROMPT (NCT04746300)
- Testing
- Biopsy, Blood sample
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Radboud University Medical Center
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
This randomized pilot study will be conducted in men with metastatic castration resistant prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide.
- Trial name
- NCT02130947
- Testing
- Exercise
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
This is a single-arm pharmacodynamic study with mandatory metastatic tumor biopsies in men with castration-resistant prostate cancer.
- Trial name
- NCT02115828
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02985021
- Testing
- Carboplatin, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Neoplasms, Prostate
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
- Trial name
- NCT07332455
- Testing
- GSK5471713
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic…
- Trial name
- NCT02053311
- Testing
- Orteronel
- Where
- 7 sites in Switzerland
- Sponsor
- Swiss Cancer Institute
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate…
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
- Trial name
- NCT03460977
- Testing
- Mevrometostat (PF-06821497), Enzalutamide, Itraconazole
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 453 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the…
- Trial name
- NCT04225910
- Testing
- 225Ac-PSMA
- Volunteers
- 20 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Metastatic Castration-resistant Prostate Cancer
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05533203
- Testing
- Prodencel; an autologous dendritic cell therapeutic tumor vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Humantech Biotechnology Co. Ltd
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate…
- Trial name
- NCT06615752
- Testing
- green tea and quercetin + docetaxel
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Charles Drew University of Medicine and Science